ARRY: Target Cuts Continue as Index Deletion Clock Ticks Down

Array Technologies is caught in a tightening vise: short interest nudged higher again this week, analysts keep cutting targets, and the passive index deletion timeline is now measured in weeks rather than months.

Short interest climbed to 25.9% of free float, up 7.8% on the day of the last reading and 3.9% on the week. That is a continuation of the rebuild that has been running since mid-September. Availability remains at zero, every share in the lending pool is out on loan, matching the 52-week floor. Yet the cost to borrow has barely moved, sitting at 0.85%, flat on the week and actually down about 21% over the past month. That combination, maximum tightness with minimal premium, tells you the short book is crowded but not under squeeze pressure. Options traders remain a notable counterweight. The put/call ratio hit 0.1523, its lowest reading of the past year, below even its 52-week low. That is call-heavy positioning, not the defensive hedging you would expect to accompany a 26% short book. The divergence between the short register and the options market has been a feature of this stock for several weeks now, and it has not resolved.

The Street is moving in one direction only. BMO Capital cut its target from $7 to $6 on Wednesday, maintaining Market Perform. JPMorgan did the same on Monday, trimming from $8 to $7 at Neutral. Those follow Morgan Stanley at $6, Barclays and Susquehanna at $4, and Mizuho's upgrade to Outperform on October 15, where the analyst raised the rating but simultaneously cut the target from $7 to $5. That particular move captures the current mood precisely: the fundamental case is improving enough to warrant a higher rating, but the near-term numbers have deteriorated enough to require a lower target. The mean target now sits at $7.40, against a stock price of $3.33. A gap that wide is either a deep value signal or evidence that targets have not fully caught down to reality. Given the pace and direction of revisions, the latter looks more likely. The EPS momentum factor score ranks in the 86th percentile on a 30-day basis, suggesting estimates have been moving up recently, but the EPS surprise score at the 17th percentile reflects a history of missing consensus. The analyst recommendation divergence score, at the 93rd percentile, shows the stock is priced well below where the aggregate analyst community thinks it belongs.

The index deletion angle has sharpened since the previous note. ORTEX puts the probability of ARRY being removed from the MSCI World Small, MSCI USA IMI, MSCI USA Small, and MSCI World IMI indices at 78% each, all tied to the November 2026 Quarterly Review. Those ranks were set on October 19. The announcement date is November 11, with the trade date on November 30 and the change effective December 1. The price that would flip the rule sits at $4.16. ARRY closed at $3.33 on Tuesday, 24.9% below that level. The combined forced selling from those four indices amounts to roughly $47M in notional flow. Separately, ORTEX puts the chance of deletion from the CRSP US Small index at 81%, with the rank date on December 4, announcement on December 7, and the trade on December 22. That adds another $7M of potential selling pressure. None of these are confirmed by the index providers yet, but the stage classifications of "decided" on the MSCI indices indicate ORTEX's model treats the outcome as near-certain at the current price.

The institutional register shows First Trust Advisors adding 10M shares as of September 30, and T. Rowe Price adding nearly 7.9M over the same period. Those are meaningful additions into a falling stock, and they sit against the activist filings data, which shows Vanguard's main entity effectively exiting a position that was over 10% of the class as recently as late 2025. Schroders and Point72 both cut back below the 5% disclosure threshold during 2025, so the institutional flow picture is mixed: some buyers emerging, but notable sellers from the prior register.

The last earnings print on August 5 sent the stock down 12.6% on the day and 13.6% over the following five days. The next report is scheduled for November 5, three weeks before the MSCI deletion trade date. How the company's order book and margin outlook read into that print will determine whether the gap between the $3.33 stock price and the $7-plus analyst targets begins to close or whether another round of downward revisions follows.